Company intelligence / Profile preview
Nanite
- Ownership
- Private
- Employees
- ~15
- Development stage
- Preclinical
Overview
Nanite is developing programmable, tissue-specific polymer nanoparticles for non-viral gene therapy. Their SAYER™ platform uses AI and high-throughput screening to engineer PNPs with improved safety and tissue targeting. The company has demonstrated strong preclinical results in animal models for efficient and specific genetic cargo delivery. Recent grants support development of DNA-based therapies for HIV using this technology; no clinical trial data reported yet.[4][5]
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- Polymer nanoparticles (PNPs) for gene deliveryDNA/RNA-based therapeutics (via non-viral vectors)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Nanite.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nanite.